SBI Securities
SPRY icon

SBI Securities’s ARS Pharmaceuticals SPRY Stock Holding History

SBI Securities’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.12K Hold
2,115
– – ﹤0.01% 1893
2026
Q2 		$16.9K Buy
2,115
+1,465
+225% +$12.6K ﹤0.01% 1607
2026
Q1 		$5.22K Sell
650
-99
-13% -$949 ﹤0.01% 2010
2025
Q4 		$8.73K Buy
749
+51
+7% +$496 ﹤0.01% 1777
2025
Q3 		$7.02K Buy
698
+48
+7% +$689 ﹤0.01% 1915
2025
Q2 		$11.3K Sell
650
-7
-1% -$101 ﹤0.01% 1649
2025
Q1 		$8.26K Sell
657
-15,896
-96% -$191K ﹤0.01% 1683
2024
Q4 		$175K Buy
+16,553
New +$232K 0.01% 583

Other funds holding SPRY

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Norman Fields Gottscho Capital Management
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
USAdvisors Wealth Management
USAdvisors Wealth Management Eden Prairie, Minnesota $351M AUM 13.01% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
CX Institutional
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Brown, Lisle/Cummings
Brown, Lisle/Cummings Providence, Rhode Island $453M AUM 20.23% 1-Year Est. Return

SBI Securities's SPRY Position: Q3 2026 in Review

SBI Securities held its ARS Pharmaceuticals (SPRY) position steady in Q3 2026 at 2,115 shares worth $9.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

SBI Securities first reported a position in SPRY in Q4 2024 and has held it in 8 quarters since. The position peaked at $175K in Q4 2024. 16 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • SBI Securities held 2,115 shares of ARS Pharmaceuticals worth $9.12K as of Q3 2026.
  • SBI Securities left its ARS Pharmaceuticals share count unchanged in Q3 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #1893 holding.
  • SBI Securities first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's ARS Pharmaceuticals position peaked at $175K in Q4 2024.
  • 16 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.